EUDA Health Holdings Limited (EUDA)

SINGAPORE, Sept. 10, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that its wholly-owned subsidiary, EUDA Health Pte. Ltd. (“EUDA Health”), has signed a Letter of Intent (the “LOI”) to potentially acquire GO POSB Organoids Pte Ltd (“GO POSB”), a biotechnology company formed in Singapore.

-        Preliminary Discussions Underway to Establish a Joint Venture

Singapore, May 08, 2024 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosystem, proudly announces the successful completion of its acquisition of CK Health Plus Sdn Bhd (“CK Health”) today. This strategic move marks an expansion of EUDA's presence in Malaysia and underscores its commitment to revolutionizing the healthcare landscape in the region.

SINGAPORE, May 06, 2024 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosystem, today announced that it will acquire CK Health Plus Sdn Bhd (“CK Health”), a direct seller of holistic wellness consumer products in Malaysia.

Singapore., Jan. 16, 2024 (GLOBE NEWSWIRE) -- As previously disclosed, EUDA Health Holdings Limited (“EUDA” and the “Company”) received a written notice from Nasdaq on January 9, 2024 indicating that the Company had failed to maintain a minimum market value of listed securities of $35 million over the previous 30 consecutive business days (the “MVLS Requirement”) as required by the Nasdaq Listing Rule 5550(b)(2).

Singapore., Jan. 16, 2024 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” and the “Company”) received a written notice (the “MVLS Notice”) from Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) on January 9, 2024 indicating that the Company had failed to maintain a Minimum Market Value of Listed Securities (“MVLS”) of $35 million over the previous 30 consecutive business days as required by the Nasdaq Listing Rule 5550(b)(2).

SINGAPORE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a Singapore-based digital health platform that aims to make healthcare more affordable, accessible, and improve the patient experience by delivering enhanced outcomes through personalized healthcare, today announced that it has signed a letter of intent dated October 4, 2023, with respect to the proposed merger with TheoremRx Inc. (“TheoremRx”), a private U.S.-based company focused on the development of new treatments with safe administration, low toxicity, and a high potential for polypharmacy usage to benefit patients suffering from cancer and women's health conditions.

Singapore, Sept. 22, 2023 (GLOBE NEWSWIRE) -- As previously disclosed, EUDA Health Holdings Limited (“EUDA” and the “Company”) received a written notice from Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) on August 10, 2023 indicating that the Company was not in compliance with the $1.00 Minimum Bid Price requirement set forth in the Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). On September 14, 2023, the Company received a written notice from Nasdaq stating that the closing bid price of the Company's common stock has been at $1.00 per share or greater for 10 consecutive business days from August 30 to September 13, 2023, and therefore the Company has regained compliance with the $1.00 Minimum Bid Price Requirement for continued listing on The Nasdaq Capital Market.

Singapore, Aug. 14, 2023 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” and the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”).

Singapore, Aug. 04, 2023 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” and the “Company”) received a notice (the “MVLS Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”), stating that the Company's listed securities failed to comply with the $35 million market value of listed securities (“Market Value of Listed Securities”) requirement for continued listing on the Nasdaq Capital Market in accordance with Nasdaq Listing Rule 5550(b)(2) based upon the Company's Market Value of Listed Securities for the 30 consecutive business days prior to the date of the MVLS Notice.